Advertisement

Advertisement

Colorectal Cancer
Bladder Cancer
Prostate Cancer
Issues in Oncology

Potential Cancer Vaccine Target Uncovered in E coli Bacteria

Targeting certain bacterial strains linked to cancer with treatments or vaccines may help to reduce the risk of colorectal cancer, urothelial carcinoma, and prostate cancer, according to a novel study published by Mäklin et al in The Lancet Microbiome. Background The bacterium Escherichia coli is...

Prostate Cancer

PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer

Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...

Breast Cancer
Lung Cancer
Hepatobiliary Cancer
Gastroesophageal Cancer
Prostate Cancer
Skin Cancer
Immunotherapy

Highlights From the ESMO Congress 2024

The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...

Breast Cancer
Gynecologic Cancers
Prostate Cancer
Pancreatic Cancer

NCCN Guidelines Expanded to Meet Growing Understanding of Hereditary Risk

The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers.1 “The recently updated NCCN Guidelines for ...

Prostate Cancer

Study Identifies New Approach to Overcome Docetaxel Resistance in Patients With Advanced Prostate Cancer

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other targets to treat prostate cancer are still necessary to prolong life and slow the progression of...

Prostate Cancer

Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer

In a prospective analysis reported in JAMA Network Open, Patel et al found that long-term health-related quality of life (HRQOL) was poorer among patients with prostate cancer who received postprostatectomy radiotherapy vs those who did not, with little difference observed among patients with early ...

Bladder Cancer
Prostate Cancer
Neuroendocrine Tumors
Immunotherapy

Pembrolizumab Plus Standard Chemotherapy May Benefit Patients With Rare, Aggressive Cancers

Researchers have found that combining the immunotherapy drug pembrolizumab with standard chemotherapy may improve treatment outcomes in patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer, according to a recent study published by Gu et al in Cell Reports Medicine....

Prostate Cancer

Study Finds Long-Term Risks Associated With Prostate Cancer Treatment and Highlights the Importance of Counseling Prior to Screening and Treatment

A large cohort study investigating the long-term treatment-related adverse effects and complications from prostate cancer treatment compared to an untreated control group has found that treatment was associated with higher rates of 10 potential complications in the 12 years after treatment. Given...

Prostate Cancer
Survivorship

Study Finds Long-Term Risks Associated With Prostate Cancer Treatment

A large cohort study investigated the long-term treatment-related adverse effects and complications from prostate cancer treatment compared with an untreated control group. The investigators found that treatment was associated with higher rates of 10 potential complications in the 12 years after...

Issues in Oncology
Breast Cancer
Kidney Cancer
Colorectal Cancer
Pancreatic Cancer
Prostate Cancer
Solid Tumors

Neoadjuvant Therapy Yields Notable Outcomes in Triple-Negative Breast Cancer

The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors.  For comprehensive news of these studies and more, visit ASCOPost.com. Triple-Negative Breast Cancer: Phase III KEYNOTE-522 The phase III KEYNOTE-522 trial has...

Prostate Cancer
Issues in Oncology

Case Study Shows Striking Improvements in Patient Treated for Metastatic Prostate Cancer With Antibody-Drug Conjugate

A landmark case report suggested a potential breakthrough in the treatment of an aggressive type of prostate cancer, according to a recent study published by Lap et al in the Annals of Internal Medicine. The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was approved by the U.S....

Solid Tumors
Lung Cancer
Prostate Cancer
Issues in Oncology
Supportive Care

Quantifying the Benefit of Smoking Cessation Within 6 Months of a Cancer Diagnosis

Quitting smoking within 6 months of receiving a cancer diagnosis could add an average of 2 years to a patient’s life, according to a recent study published by Cinciripini et al in JAMA Oncology. The findings demonstrated a broad survival benefit of using evidence-based smoking cessation to help...

Prostate Cancer
Issues in Oncology

Using AI to Measure Prostate Cancer Lesions Could Aid Diagnosis and Treatment

Researchers have trained and validated an artificial intelligence (AI) model based on magnetic resonance imaging (MRI) scans to develop a consistent method of estimating prostate cancer lesion size, according to a recent study published by Yang et al in Radiology. The findings could aid physicians...

Prostate Cancer

SBRT vs Conventional Radiotherapy for Localized Prostate Cancer

As reported in The New England Journal of Medicine by van As et al, the phase III PACE-B trial has shown noninferiority of stereotactic body radiotherapy (SBRT) vs conventionally fractionated radiotherapy in biochemical or clinical failure in patients with low- to intermediate-risk localized...

Prostate Cancer

Updated Findings in Prostate Cancer Screening With Systemic Biopsy vs MRI-Targeted Biopsy

Updated results of a Swedish screening study (GOTEBORG-2), reported in The New England Journal of Medicine by Hugosson et al, indicate that omitting biopsy among individuals with negative magnetic resonance imaging (MRI) results eliminated a high proportion of diagnoses of clinically insignificant...

Prostate Cancer
Genomics/Genetics

African Men May Have Higher Risk of Developing Prostate Cancer Earlier

Researchers have identified genetic risk factors that may contribute to prostate cancer in a diverse group of African men, according to a recent study published by Janivara et al in Nature Genetics. The findings could uncover new treatment options in this patient population. Background Certain...

Prostate Cancer
Issues in Oncology

Two Universities to Develop Incisionless Prostate Cancer Surgery Using MRI and Robotics

Researchers at Case Western Reserve University and Vanderbilt University have received a $3.7 million grant from the National Cancer Institute to pioneer a novel approach to prostate cancer surgery that combines advanced robotics and low-field magnetic resonance imaging (MRI) technology. Overview...

Prostate Cancer

Can Blood Test Predict Survival in Metastatic Prostate Cancer?

A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who...

Prostate Cancer

Transperineal vs Transrectal Prostate Biopsy for Suspicion of Prostate Cancer

In the PREVENT trial, reported as a research letter in JAMA Oncology, Hu et al found that transperineal prostate biopsy resulted in less risk of infection than transrectal biopsy in patients with suspicion of prostate cancer, with no difference between methods observed in detecting high-grade...

Prostate Cancer

PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer

Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...

Prostate Cancer

LuPSMA vs Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients With Metastatic Castration-Resistant Prostate Cancer

As reported in The Lancet by Morris et al, the phase III PSMAfore trial has shown improved progression-free survival with lutetium-177–labeled PSMA-617 (LuPSMA) vs change in androgen receptor pathway inhibitor (ARPI) in taxane-naive patients with metastatic castration-resistant prostate cancer...

Prostate Cancer
Issues in Oncology

Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer

Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings...

Solid Tumors
Lung Cancer
Colorectal Cancer
Prostate Cancer
Issues in Oncology

Conversations Between Physicians and Older Patients About Physical Activity May Reduce Falls During Cancer Treatment

Communication between health-care providers and older patients with cancer regarding the significance of physical activity may help reduce the risk of falls during cancer therapy, according to new findings presented by Lu and Zheng at the 2024 ASCO Quality Care Symposium (Abstract 224). Background...

Prostate Cancer
Issues in Oncology

Neighborhood Environment May Be Linked to Prostate Cancer Risk in Men With West African Genetic Ancestry

West African genetic ancestry may be associated with an increased risk of prostate cancer among men residing in disadvantaged neighborhoods but not among those residing in more affluent neighborhoods, according to a recent study published by Pichardo et al in JAMA Network Open. The findings...

Prostate Cancer

Addition of Lu-177–PSMA-617 to Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

In an Australian phase II trial (UpFrontPSMA) reported in The Lancet Oncology, Azad et al found that sequential lutetium (Lu)-177–prostate-specific membrane antigen (PSM)-617 (Lu-177–PSMA-617) and docetaxel was superior to docetaxel alone in achieving undetectable prostate-specific antigen (PSA)...

Prostate Cancer
Issues in Oncology

High Proportion of U.S. Men Older Than 45 Years May Have Misconceptions About Prostate Cancer Screening as Rates of Late-Stage Diagnoses Continue to Rise

Investigators have uncovered misconceptions and gaps in awareness regarding prostate cancer and screening guidelines in light of Prostate Cancer Awareness Month in September, according to a recent survey conducted by The Harris Poll. Background In 2024, an estimated 299,010 men will be diagnosed...

Prostate Cancer

Prostate Cancer Mortality and 5-ARI Use

In a Canadian study reported in JAMA Network Open, Hamilton et al found that use of 5-alpha reductase inhibitors (5-ARIs) prior to the diagnosis of prostate cancer was not associated with an increased risk of prostate cancer–specific or overall mortality. Study Details The study involved data from...

Prostate Cancer
Issues in Oncology

Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer

Olaparib may be effective in treating men with biochemically recurrent prostate cancer without accompanying hormone therapy, according to a novel study published by Marshall et al in JAMA Oncology. Background Although most men with localized prostate cancer can be cured with surgery or primary...

Cost of Care
Breast Cancer
Gynecologic Cancers
Colorectal Cancer
Lung Cancer
Prostate Cancer

Cancer Screening Estimated to Cost $43 Billion Annually in United States

Cancer screening may cost more than $40 billion annually in the United States, according to a recent study published by Halpern et al in the Annals of Internal Medicine. Study Methods and Results In the recent modeling study, investigators used national health-care survey and cost resources data to ...

Colorectal Cancer
Prostate Cancer
Pancreatic Cancer
Breast Cancer
Gynecologic Cancers
Issues in Oncology
Supportive Care

Common Blood Tests May Improve Early Cancer Diagnosis

The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...

Prostate Cancer

Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer

In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Study Details In the ...

Prostate Cancer
Issues in Oncology

Is Lower-Dose Radiopharmaceutical Therapy Effective in Advanced Prostate Cancer?

Treatment with de-escalated actinium (Ac)-225–prostate-specific membrane antigen (PSMA)-617 or a combination of lutetium (Lu)-177/Ac-225–PSMA-617 resulted in similar median overall survival and prostate-specific antigen (PSA) response rates and better tolerance among patients with advanced-stage...

Prostate Cancer
Cardio-oncology

Patients With Prostate Cancer: Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Based on the results of a retrospective cohort study published by Demissei et al in JACC: CardioOncology, Black patients with prostate cancer who received systemic androgen-deprivation therapy (ADT) seemed to have a significantly greater likelihood of experiencing adverse cardiovascular disease...

Prostate Cancer
Issues in Oncology

Liquid Biopsy May Enable Monitoring of Disease Evolution in Patients With Metastatic Prostate Cancer

DNA/RNA material contained in circulating extracellular vesicles secreted into the blood stream by tumor cells may capture cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a recent study published by Casanova et al in Cancer Cell. Background...

Prostate Cancer
Genomics/Genetics

Can Living in a Disadvantaged Area Increase the Risk of Aggressive Prostate Cancer?

Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, new research suggests, which in turn may contribute to higher rates of aggressive prostate cancer in African American men. These findings were published by Boyle et al in JAMA Network Open....

Prostate Cancer
Cost of Care

Out-of-Pocket Costs From Diagnostic Testing After Prostate Cancer Screening

Prostate-specific antigen (PSA) screening aims to identify patients who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive—and expensive—diagnostic testing to establish a diagnosis. New research reveals that the out-of-pocket costs for such...

Prostate Cancer

Prostate Cancer Detection With AI vs Radiologist Readings of MRI

In a study reported in The Lancet Oncology (PI-CAI), Saha et al found that an artificial intelligence (AI) system’s readings of magnetic resonance imaging (MRI) outperformed study radiologist readings using Prostate Imaging—Reporting and Data System (PI-RADS) version 2.1 in detecting clinically...

Prostate Cancer
Genomics/Genetics

Association of Genetic Risk for Prostate Cancer With Early Prostate Cancer Death

In a study reported in JAMA Network Open, Plym et al found that men at a higher genetic risk for prostate cancer were more likely to experience early death from prostate cancer compared to men with a lower genetic risk for the disease. Study Details The cohort study used a combined analysis of...

Prostate Cancer
Issues in Oncology

Certain Patients Diagnosed With 'Benign' Classification of Prostate Cancer May Actually Have High-Risk Disease

Recently, some experts have called for Gleason Grade Group 1 prostate cancer to be reclassified as benign. However, many patients diagnosed with this lowest grade of prostate cancer may have more aggressive disease than their biopsy alone suggests, according to a recent study published by Tilki et...

Prostate Cancer

MAST Trial: Metformin Does Not Slow Disease Progression of Low-Risk Prostate Cancer

The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlled MAST trial reported at the 2024 ASCO Annual Meeting.1 In addition, the use of metformin was...

Prostate Cancer
Issues in Oncology

PSA May Be Insufficient to Detect Early Prostate Cancer in Transgender Women

Transgender women receiving hormone therapy may skew artificially low on prostate cancer screening tests, thereby providing false reassurance and potentially delaying diagnosis and treatment, according to a recent study published by Nik-Ahd et al in JAMA. The findings indicated that transgender...

Colorectal Cancer
Breast Cancer
Gynecologic Cancers
Prostate Cancer
Issues in Oncology

Study Evaluates Cancer Screening Behaviors Among a Population of Muslim Individuals

Investigators uncovered crucial insights into the cancer screening behaviors of a population of Muslim individuals residing in the Washington, DC, metropolitan area that could help illuminate the influence of cultural and religious beliefs on health practices, according to a recent study published...

Prostate Cancer
Issues in Oncology

Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer

Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...

Prostate Cancer
Issues in Oncology
Supportive Care

Chelating Agent May Reduce Toxicity Associated With PSMA Radiopharmaceutical Therapy

A novel chelator may significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to new findings presented by Ho et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 242340). Background...

Prostate Cancer

Low-Risk Prostate Cancer: Disease-Free Survival With Hypofractionated vs Conventionally Fractionated Radiotherapy

As reported in the Journal of Clinical Oncology by W. Robert Lee, MD, MS, and colleagues, a 12-year analysis of the phase III NRG Oncology RTOG 0415 trial has shown continued noninferiority in terms of disease-free survival with hypofractionated radiotherapy vs conventionally fractionated...

Prostate Cancer

Prostate Cancer: Adjuvant Radiotherapy With 6 Months of ADT vs No ADT

In a component of the phase III RADICALS-HD trial reported in The Lancet, Chris C. Parker, MD, and colleagues found that metastasis-free survival was not significantly improved with 6 months of androgen-deprivation therapy (ADT) vs no ADT together with adjuvant radiotherapy in patients with...

Prostate Cancer

Adjuvant Radiotherapy With 24 vs 6 Months of ADT in Prostate Cancer

In a component of the phase III RADICALS-HD trial reported in The Lancet, Parker et al found that metastasis-free survival was improved with the addition of 24 months vs 6 months of androgen-deprivation therapy (ADT) to adjuvant radiotherapy in prostate cancer. A second component of the trial, not...

prostate cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

prostate cancer

Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).

prostate cancer

Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).

Advertisement

Advertisement

Advertisement